Immuneering (US:IMRX) Globenewswireยท2025-06-17 10:00Core Insights - Immuneering Corporation announced positive results from its Phase 2a clinical trial of atebimetinib (IMM-1-104) in combination with modified gemcitabine/nab-paclitaxel (mGnP) for first-line pancreatic cancer patients, showing a 94% overall survival (OS) at 6 months and a 72% progression-free survival (PFS) at the same time point [2][3][6] Group 1: Clinical Trial Results - The trial reported a 39% overall response rate (ORR) and an 81% disease control rate (DCR), with many patients experiencing deepening and durable regressions [6][9] - The median OS and PFS have not yet been reached, indicating ongoing efficacy [6] - The tolerability profile of atebimetinib in combination with mGnP was markedly favorable, with no Grade 3+ adverse events observed in most categories [6][10] Group 2: Future Plans and Milestones - A pivotal trial for atebimetinib in combination with mGnP is planned for 2026, reflecting the company's commitment to advancing this treatment option [1][11][14] - The company has increased target enrollment for the trial to approximately 50 patients based on the encouraging data [6][11] - Immuneering will host a conference call to discuss the data and provide a business update, indicating proactive communication with stakeholders [11]